Symbols / TWST Stock $69.11 +1.98% Twist Bioscience Corporation

Healthcare • Diagnostics & Research • United States • NMS
TWST (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Emily Marine Leproust Ph.D.
Exch · Country NMS · United States
Market Cap 4.30B
Enterprise Value 4.16B
Income -81.28M
Sales 409.48M
FCF (ttm) -58.48M
Book/sh 7.32
Cash/sh 2.76
Employees 979
Insider 10d —
IPO Oct 31, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -33.71
PEG —
P/S 10.51
P/B 9.44
P/C —
EV/EBITDA -37.87
EV/Sales 10.16
Quick Ratio 2.04
Current Ratio 2.70
Debt/Eq 24.36
LT Debt/Eq —
EPS (ttm) -1.32
EPS next Y -2.05
EPS Growth —
Revenue Growth 19.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-03
Earnings (prior) 2026-05-04
ROA -12.93%
ROE -18.16%
ROIC —
Gross Margin 52.07%
Oper. Margin -34.92%
Profit Margin -19.85%
Shs Outstand 62.27M
Shs Float 55.41M
Insider Own 1.26%
Instit Own 123.93%
Short Float 30.69%
Short Ratio 9.29
Short Interest 14.90M
52W High 80.50
vs 52W High -14.15%
52W Low 23.30
vs 52W Low 196.61%
Beta 2.21
Impl. Vol. 74.07%
Rel Volume 0.60
Avg Volume 1.40M
Volume 841.64K
Target (mean) $64.38
Tgt Median $65.50
Tgt Low $36.00
Tgt High $80.00
# Analysts 8
Recom Strong_buy
Prev Close $67.77
Price $69.11
Change 1.98%
About

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$64.38
Mean price target
2. Current target
$70.40
Latest analyst target
3. DCF / Fair value
$-16.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$70.40
Low
$36.00
High
$80.00
Mean
$64.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-11 init Piper Sandler Overweight → Overweight $85
2026-05-05 up Leerink Partners Market Perform → Outperform $70
2026-05-05 main Barclays Overweight → Overweight $65
2026-05-05 main Guggenheim Buy → Buy $60
2026-05-05 main Baird Outperform → Outperform $65
2026-04-14 main Barclays Overweight → Overweight $55
2026-04-06 main Evercore ISI Group Outperform → Outperform $56
2026-03-30 main Guggenheim Buy → Buy $55
2026-02-03 main Evercore ISI Group Outperform → Outperform $52
2026-02-03 main Barclays Overweight → Overweight $50
2026-01-26 main Guggenheim Buy → Buy $50
2026-01-08 main TD Cowen Buy → Buy $43
2025-12-15 main Barclays Overweight → Overweight $39
2025-11-17 main Barclays Overweight → Overweight $37
2025-11-04 init Stephens & Co. — → Overweight $41
2025-10-07 main Evercore ISI Group Outperform → Outperform $42
2025-10-02 main Barclays Overweight → Overweight $40
2025-05-06 main Goldman Sachs Buy → Buy $48
2025-05-06 reit Guggenheim Buy → Buy $50
2025-05-06 main Baird Outperform → Outperform $44
News
RSS: Latest TWST news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-08 CHO DENNIS Officer — 402 $69.84 $28,077
2026-06-08 WERNER ROBERT F. Officer — 1,359 $69.07 $94,046
2026-06-08 GREEN PAULA Officer — 884 $69.84 $61,742
2026-06-08 LEPROUST EMILY M Chief Executive Officer — 2,265 $69.84 $158,197
2026-06-08 WERNER ROBERT F. Officer — 500 $0.00 $0
2026-05-29 CHO DENNIS Officer — 14,205 $69.75 $990,799
2026-05-29 LAPONIS ADAM Chief Financial Officer — 4,000 $70.00 $280,000
2026-05-28 STAROVASNIK MELISSA A Director — 2,500 $68.00 $170,000
2026-05-28 LEPROUST EMILY M Chief Executive Officer — 16,470 $65.33 $1,118,555
2026-05-28 LEPROUST EMILY M Chief Executive Officer — 16,470 $8.82 $145,265
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
376.57
+20.32%
312.97
+27.69%
245.11
+20.41%
203.56
Operating Revenue
376.57
+20.32%
312.97
+27.69%
245.11
+20.41%
203.56
Cost Of Revenue
185.57
+3.31%
179.62
+15.60%
155.38
+30.21%
119.33
Reconciled Cost Of Revenue
185.57
+3.31%
179.62
+15.60%
155.38
+30.21%
119.33
Gross Profit
191.00
+43.23%
133.35
+48.61%
89.73
+6.52%
84.23
Operating Expense
327.26
+5.82%
309.25
+4.25%
296.63
-10.99%
333.26
Research And Development
80.28
-11.63%
90.85
-15.01%
106.89
-11.15%
120.31
Selling General And Administration
246.98
+13.09%
218.40
+15.11%
189.74
-10.90%
212.95
Total Expenses
512.83
+4.90%
488.88
+8.16%
452.01
-0.13%
452.59
Operating Income
-136.26
+22.54%
-175.90
+14.98%
-206.90
+16.91%
-249.02
Total Operating Income As Reported
-136.26
+38.30%
-220.83
-1.69%
-217.16
+7.50%
-234.78
EBITDA
-111.41
+22.89%
-144.47
+18.65%
-177.59
+16.10%
-211.68
Normalized EBITDA
-160.25
-61.00%
-99.54
+40.52%
-167.34
+27.41%
-230.53
Reconciled Depreciation
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
EBIT
-136.26
+22.54%
-175.90
+14.98%
-206.90
+9.33%
-228.19
Total Unusual Items
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Total Unusual Items Excluding Goodwill
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Special Income Charges
48.85
+208.72%
-44.93
-338.09%
-10.26
-154.40%
18.85
Impairment Of Capital Assets
0.00
-100.00%
44.93
+562.20%
6.79
0.00
Restructuring And Mergern Acquisition
0.00
0.00
-100.00%
3.47
+124.37%
-14.24
Net Income
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Pretax Income
-76.95
+63.03%
-208.17
-2.31%
-203.47
+10.87%
-228.27
Net Non Operating Interest Income Expense
11.36
-25.94%
15.34
+6.82%
14.37
+381.72%
2.98
Interest Expense Non Operating
—
0.03
+480.00%
0.01
-93.75%
0.08
Net Interest Income
11.36
-25.94%
15.34
+6.82%
14.37
+381.72%
2.98
Interest Expense
—
0.03
+480.00%
0.01
-93.75%
0.08
Interest Income Non Operating
11.36
-25.94%
15.34
+6.82%
14.37
+369.14%
3.06
Interest Income
11.36
-25.94%
15.34
+6.82%
14.37
+369.14%
3.06
Other Income Expense
47.94
+200.70%
-47.61
-335.66%
-10.93
-161.51%
17.77
Other Non Operating Income Expenses
-0.90
+66.29%
-2.68
-298.66%
-0.67
+38.18%
-1.09
Gain On Sale Of Business
48.85
0.00
0.00
-100.00%
4.61
Tax Provision
0.72
+28.39%
0.56
-51.39%
1.15
+111.07%
-10.41
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+320.00%
0.00
Tax Effect Of Unusual Items
10.26
0.00
+100.00%
-2.15
-328.49%
0.94
Net Income Including Noncontrolling Interests
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income From Continuing Operation Net Minority Interest
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income From Continuing And Discontinued Operation
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Net Income Continuous Operations
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Normalized Income
-116.26
+29.02%
-163.80
+16.65%
-196.52
+16.65%
-235.77
Net Income Common Stockholders
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Diluted EPS
-1.30
+63.89%
-3.60
+0.00%
-3.60
+10.89%
-4.04
Basic EPS
-1.30
+63.89%
-3.60
+0.00%
-3.60
+10.89%
-4.04
Basic Average Shares
59.81
+3.09%
58.02
+1.99%
56.88
+5.57%
53.88
Diluted Average Shares
59.81
+3.09%
58.02
+1.99%
56.88
+5.57%
53.88
Diluted NI Availto Com Stockholders
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
641.86
+4.48%
614.32
-20.88%
776.40
-19.24%
961.38
Current Assets
332.97
-3.98%
346.78
-18.26%
424.26
-28.87%
596.48
Cash Cash Equivalents And Short Term Investments
232.43
-15.91%
276.40
-17.84%
336.41
-33.38%
504.97
Cash And Cash Equivalents
183.05
-19.12%
226.32
-21.00%
286.47
-24.35%
378.69
Cash Equivalents
150.37
-24.76%
199.86
-18.64%
245.65
—
Cash Financial
32.68
+23.51%
26.46
-35.18%
40.82
—
Other Short Term Investments
49.38
-1.39%
50.08
+0.28%
49.94
-60.45%
126.28
Receivables
57.02
+63.36%
34.90
-20.79%
44.06
+9.36%
40.29
Accounts Receivable
57.02
+63.36%
34.90
-20.79%
44.06
+9.36%
40.29
Gross Accounts Receivable
57.62
+61.84%
35.60
-19.57%
44.26
+9.31%
40.49
Allowance For Doubtful Accounts Receivable
-0.60
+14.29%
-0.70
-250.00%
-0.20
+0.00%
-0.20
Receivables Adjustments Allowances
—
—
—
-0.23
Other Receivables
—
—
—
4.82
Inventory
28.31
+17.57%
24.08
-24.90%
32.06
-18.43%
39.31
Raw Materials
20.19
+16.60%
17.32
-35.92%
27.02
-6.12%
28.79
Work In Process
2.27
+5.55%
2.15
+92.81%
1.11
-61.17%
2.87
Finished Goods
5.85
+26.80%
4.62
+17.58%
3.93
-48.71%
7.65
Prepaid Assets
—
—
—
11.91
Other Current Assets
15.20
+33.42%
11.40
-2.73%
11.72
-1.66%
11.91
Total Non Current Assets
308.89
+15.45%
267.55
-24.02%
352.15
-3.49%
364.90
Net PPE
151.66
-6.00%
161.35
-20.66%
203.36
-5.14%
214.39
Gross PPE
246.65
+4.08%
236.99
-6.70%
254.02
+3.19%
246.17
Accumulated Depreciation
-94.99
-25.58%
-75.64
-49.33%
-50.66
-59.41%
-31.78
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
17.30
+4.86%
16.50
+35.47%
12.18
+78.06%
6.84
Construction In Progress
20.12
+329.10%
4.69
-45.03%
8.53
-90.28%
87.72
Other Properties
150.96
-4.67%
158.36
-10.04%
176.04
+28.28%
137.23
Leases
58.28
+1.44%
57.45
+0.31%
57.27
+298.52%
14.37
Goodwill And Other Intangible Assets
95.62
-4.66%
100.29
-28.52%
140.29
-3.61%
145.55
Goodwill
82.19
-4.21%
85.81
+0.00%
85.81
+0.00%
85.81
Other Intangible Assets
13.43
-7.27%
14.48
-73.43%
54.48
-8.80%
59.74
Investments And Advances
54.34
+3463.08%
1.52
—
—
Other Non Current Assets
7.28
+66.01%
4.38
-48.37%
8.49
+71.31%
4.96
Total Liabilities Net Minority Interest
168.90
+19.25%
141.63
-7.41%
152.97
-11.06%
171.99
Current Liabilities
91.41
+28.73%
71.01
-3.16%
73.32
-19.13%
90.66
Payables And Accrued Expenses
38.69
+98.83%
19.46
-33.31%
29.18
-13.98%
33.92
Payables
15.64
+259.06%
4.36
-76.36%
18.43
-22.43%
23.75
Accounts Payable
11.09
+580.61%
1.63
-88.40%
14.05
-30.06%
20.09
Other Payable
—
—
—
—
Current Accrued Expenses
23.05
+52.63%
15.10
+40.45%
10.75
+5.75%
10.17
Pensionand Other Post Retirement Benefit Plans Current
31.29
-7.02%
33.65
+30.34%
25.82
-4.46%
27.02
Total Tax Payable
4.54
+66.72%
2.73
-37.70%
4.37
+19.48%
3.66
Current Debt And Capital Lease Obligation
13.82
-6.64%
14.80
-0.61%
14.90
+9.19%
13.64
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
13.82
-6.64%
14.80
-0.61%
14.90
+9.19%
13.64
Current Deferred Liabilities
6.88
+223.04%
2.13
-28.94%
3.00
-13.72%
3.48
Current Deferred Revenue
6.88
+223.04%
2.13
-28.94%
3.00
-13.72%
3.48
Other Current Liabilities
0.72
-24.87%
0.96
+123.49%
0.43
-96.59%
12.60
Total Non Current Liabilities Net Minority Interest
77.50
+9.73%
70.63
-11.32%
79.65
-2.07%
81.33
Long Term Debt And Capital Lease Obligation
61.75
-12.06%
70.22
-11.31%
79.17
-2.58%
81.27
Long Term Capital Lease Obligation
61.75
-12.06%
70.22
-11.31%
79.17
-2.58%
81.27
Non Current Deferred Liabilities
15.00
0.00
—
—
Non Current Deferred Revenue
15.00
0.00
—
—
Other Non Current Liabilities
0.75
+83.54%
0.41
-14.32%
0.47
+691.67%
0.06
Stockholders Equity
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Common Stock Equity
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
60.63
+2.98%
58.88
+2.29%
57.56
+1.83%
56.52
Ordinary Shares Number
60.63
+2.98%
58.88
+2.29%
57.56
+1.83%
56.52
Additional Paid In Capital
1,793.16
+4.55%
1,715.12
+3.49%
1,657.22
+2.32%
1,619.64
Retained Earnings
-1,319.58
-6.25%
-1,241.91
-20.22%
-1,033.03
-24.70%
-828.42
Gains Losses Not Affecting Retained Earnings
-0.63
-20.11%
-0.52
+30.95%
-0.76
+58.98%
-1.84
Other Equity Adjustments
-0.63
-20.11%
-0.52
+30.95%
-0.76
+58.98%
-1.84
Total Equity Gross Minority Interest
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Total Capitalization
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Working Capital
241.56
-12.41%
275.77
-21.42%
350.93
-30.62%
505.82
Invested Capital
472.96
+0.06%
472.69
-24.18%
623.43
-21.02%
789.38
Total Debt
75.57
-11.12%
85.03
-9.61%
94.07
-0.89%
94.91
Capital Lease Obligations
75.57
-11.12%
85.03
-9.61%
94.07
-0.89%
94.91
Net Tangible Assets
377.34
+1.33%
372.40
-22.92%
483.14
-24.96%
643.84
Tangible Book Value
377.34
+1.33%
372.40
-22.92%
483.14
-24.96%
643.84
Available For Sale Securities
54.34
+3463.08%
1.52
—
—
Investmentin Financial Assets
54.34
+3463.08%
1.52
—
—
Non Current Note Receivables
—
—
—
0.00
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-47.63
+25.69%
-64.09
+55.01%
-142.47
-14.54%
-124.39
Cash Flow From Continuing Operating Activities
-47.63
+25.69%
-64.09
+55.01%
-142.47
-14.54%
-124.39
Net Income From Continuing Operations
-77.67
+62.79%
-208.73
-2.01%
-204.62
+6.08%
-217.86
Depreciation Amortization Depletion
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
Depreciation And Amortization
24.85
-20.93%
31.43
+7.24%
29.31
+77.49%
16.51
Other Non Cash Items
2.18
+12.87%
1.93
+160.06%
-3.22
-144.33%
7.26
Stock Based Compensation
64.46
+26.58%
50.92
+68.19%
30.28
-61.99%
79.66
Provisionand Write Offof Assets
—
—
—
-0.01
Asset Impairment Charge
0.00
-100.00%
44.93
+562.20%
6.79
0.00
Operating Gains Losses
-48.85
—
—
-4.61
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-12.61
-181.80%
15.41
+1627.35%
-1.01
+81.16%
-5.36
Change In Receivables
-22.38
-365.06%
8.44
+295.46%
-4.32
+55.10%
-9.62
Changes In Account Receivables
-22.38
-365.06%
8.44
+295.46%
-4.32
+55.10%
-9.62
Change In Inventory
-4.23
-152.96%
7.99
+10.33%
7.24
+196.05%
-7.54
Change In Prepaid Assets
-3.72
-1073.04%
0.38
+109.17%
-4.17
-63.31%
-2.55
Change In Payables And Accrued Expense
12.68
+2514.02%
0.48
+147.13%
-1.03
-107.09%
14.50
Change In Accrued Expense
3.35
-72.77%
12.29
+730.97%
1.48
-79.23%
7.12
Change In Payable
9.33
+179.05%
-11.80
-370.69%
-2.51
-133.97%
7.38
Change In Account Payable
9.33
+179.05%
-11.80
-370.69%
-2.51
-133.97%
7.38
Change In Other Working Capital
—
—
—
4.85
Change In Other Current Assets
-1.57
-463.81%
0.43
-68.68%
1.38
-81.08%
7.27
Change In Other Current Liabilities
6.61
+385.37%
-2.32
-2045.37%
-0.11
+98.55%
-7.42
Investing Cash Flow
-24.76
-706.32%
-3.07
-106.07%
50.61
+121.73%
-232.93
Cash Flow From Continuing Investing Activities
-24.76
-706.32%
-3.07
-106.07%
50.61
+121.73%
-232.93
Net PPE Purchase And Sale
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Purchase Of PPE
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Capital Expenditure
-28.00
-451.69%
-5.08
+81.73%
-27.78
+72.73%
-101.86
Net Investment Purchase And Sale
0.74
-62.99%
2.00
-97.44%
78.39
+166.91%
-117.16
Purchase Of Investment
-49.39
+4.84%
-51.91
+32.01%
-76.34
+64.92%
-217.64
Sale Of Investment
50.13
-7.00%
53.91
-65.16%
154.74
+54.00%
100.48
Net Business Purchase And Sale
2.50
0.00
0.00
+100.00%
-13.91
Purchase Of Business
—
0.00
0.00
+100.00%
-13.91
Gain Loss On Sale Of Business
-48.85
0.00
0.00
+100.00%
-4.61
Net Other Investing Changes
—
—
—
-5.75
Financing Cash Flow
28.54
+314.22%
6.89
+656.31%
0.91
-99.66%
270.53
Cash Flow From Continuing Financing Activities
28.54
+314.22%
6.89
+656.31%
0.91
-99.66%
270.53
Net Issuance Payments Of Debt
—
0.00
0.00
+100.00%
-1.56
Repayment Of Debt
—
0.00
0.00
+100.00%
-1.56
Long Term Debt Payments
—
0.00
0.00
+100.00%
-1.56
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-1.56
Net Common Stock Issuance
-0.02
+99.60%
-3.98
+9.76%
-4.41
-101.68%
262.07
Common Stock Payments
-0.02
+99.60%
-3.98
+9.76%
-4.41
+43.19%
-7.75
Repurchase Of Capital Stock
-0.02
+99.60%
-3.98
+9.76%
-4.41
+43.19%
-7.75
Proceeds From Stock Option Exercised
13.56
+24.77%
10.87
+104.38%
5.32
-46.97%
10.02
Net Other Financing Charges
15.00
—
—
—
Changes In Cash
-43.85
+27.25%
-60.27
+33.73%
-90.95
-4.81%
-86.78
Effect Of Exchange Rate Changes
0.14
+13.49%
0.13
+566.67%
-0.03
+91.54%
-0.32
Beginning Cash Position
229.13
-20.79%
289.28
-23.93%
380.26
-18.64%
467.36
End Cash Position
185.43
-19.08%
229.13
-20.79%
289.28
-23.93%
380.26
Free Cash Flow
-75.63
-9.34%
-69.17
+59.37%
-170.25
+24.75%
-226.24
Interest Paid Supplemental Data
—
0.00
0.00
-100.00%
0.01
Income Tax Paid Supplemental Data
0.68
+98.55%
0.34
-18.10%
0.42
+70.73%
0.25
Amortization Of Securities
—
—
—
1.31
Common Stock Issuance
—
0.00
0.00
-100.00%
269.82
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
269.82
Sale Of Business
2.50
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category